Categories

April 15, 2025

iOmx Therapeutics Receives Regulatory Approval of Clinical Trial Application for IOMX-0675

December 19, 2024

iOmx Therapeutics submits Clinical Trial Application for IOMX-0675

August 22, 2024

iOmx Therapeutics Initiates Phase Ib with OMX-0407

June 27, 2024

iOmx Therapeutics Appoints Florian Schmid as New Chief Financial Officer

April 3, 2024

iOmx to present new data on lead programs and I/O target screening platform at AACR 2024

November 1, 2023

iOmx Therapeutics attends upcoming scientific and industry conferences